Simonetto AI-ECG (cirrhosis)
2026
Detection of Undiagnosed Liver Cirrhosis via AI-Enabled Electrocardiogram: a Pragmatic, Cluster-Randomized Clinical Trial
In 15,596 adults having a routine ECG in primary care, an AI-ECG alert for advanced chronic liver disease increased new diagnoses of chronic liver disease with advanced fibrosis within 180 days compared with usual care.
Result
Efficacy: New diagnosis of chronic liver disease with advanced fibrosis within 180 days of the ECGOR 2.09 (95% CI 1.22-3.55) · P = 0.007
Below 1 favours usual care, above 1 favours an AI-ECG alert for advanced chronic liver disease.
- Absolute difference
- 0.5 points
- NNT
- 200
Absolute difference and NNT are derived from the event rates.
Also reported: Among ECG-ML-positive patients 4.4% vs 1.1% (OR 4.37, 95% CI 1.94–9.88; P<0.001); any fibrosis (secondary) 1.7% vs 0.5% (OR 3.17, 95% CI 1.86–5.40; P<0.001).
- Subtopic
- Implementation & new uses
- Design
- Pragmatic cluster RCT (98 primary care teams)
- Relevance
- Important: one of several pillars.
- Source
- Simonetto DA, et al. Nat Med. 2026;32(1):160-167.doi 10.1038/s41591-025-04058-y
Discussion & critique
Extends the EAGLE design beyond the heart: a routine ECG becomes a case-finding test for a non-cardiac disease, with targeted liver testing downstream. The diagnostic yield stayed well below epidemiological estimates of advanced CLD prevalence, which the authors attribute to variable clinician adherence to the AI recommendation, the same adoption bottleneck seen in EAGLE and Rushlow. Diagnosis, not liver outcomes, was the endpoint; open-label cluster design.